|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Protagonist Therapeutics Inc.
| | | Phone: | (408) 649-7370 | Year Established: | 2001 | Main Contact: | Dinesh V. Patel, Ph.D., President & CEO | | Other Contacts: | Lucio Tozzi, enior Director of Clinical Operations Thamil Annamalai, M.S., Senior Director of Preclinical Development William Hodder, Senior VP, Corporate Development Richard S. Shames, M.D., CMO Tom O’Neil, CFO David Y. Liu, Ph.D., CSO & Head, R&D Ashok Bhandari, Ph.D., VP, Chemistry Larry Mattheakis, Ph.D., VP, Biology Mark Smythe, Ph.D., Founder & VP, Technology & Alliances
| | Company Description | Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target the same biological pathways for which there are marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer preferential drug exposure in the GI tissue compartment, the potential for improved safety due to minimal exposure in the blood, improved convenience and compliance, and potentially an opportunity for the earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's oral peptide product candidates, PTG-100 and PTG-200, are based on this approach with the potential to transform the existing treatment paradigm for IBD, that includes both ulcerative colitis and Crohn's disease. | |
|
|
|
|
|